Companies Cryptocurrencies
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
Exchange: NasdaqGS
IPO Date: 18/07/2018
CEO: Dr. R. Scott Struthers
Biotechnology Healthcare đź”—
  • CRNX
  • 19.49
  • 768198336
    market cap
  • -0.03000069
If you bought

shares of Crinetics Pharmaceuticals Inc (CRNX) on
You would have made
Old Price $12 Current Price $12

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 47 full-time employees. The firm is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. The company develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. The company also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The firm also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.

Address: 10222 Barnes Canyon Rd Bldg 2 San Diego CALIFORNIA 92121

Stay updated.